ES2633343T3 - Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal - Google Patents
Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal Download PDFInfo
- Publication number
- ES2633343T3 ES2633343T3 ES12800251.6T ES12800251T ES2633343T3 ES 2633343 T3 ES2633343 T3 ES 2633343T3 ES 12800251 T ES12800251 T ES 12800251T ES 2633343 T3 ES2633343 T3 ES 2633343T3
- Authority
- ES
- Spain
- Prior art keywords
- angioedema
- anaphylaxis
- asthma
- methods
- lung injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 17
- 206010002198 Anaphylactic reaction Diseases 0.000 title 1
- 208000028185 Angioedema Diseases 0.000 title 1
- 208000004852 Lung Injury Diseases 0.000 title 1
- 206010028735 Nasal congestion Diseases 0.000 title 1
- 206010069363 Traumatic lung injury Diseases 0.000 title 1
- 230000036783 anaphylactic response Effects 0.000 title 1
- 208000003455 anaphylaxis Diseases 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- 231100000515 lung injury Toxicity 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 230000009269 systemic vascular permeability Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229960000367 inositol Drugs 0.000 abstract 1
- 230000006916 protein interaction Effects 0.000 abstract 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 1
- 239000001226 triphosphate Substances 0.000 abstract 1
- 101000975401 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 3 Proteins 0.000 description 9
- 102100024035 Inositol 1,4,5-trisphosphate receptor type 3 Human genes 0.000 description 9
- 230000003993 interaction Effects 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 101150111584 RHOA gene Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496409P | 2011-06-13 | 2011-06-13 | |
| US201161496409P | 2011-06-13 | ||
| PCT/US2012/042118 WO2012174028A2 (en) | 2011-06-13 | 2012-06-13 | Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2633343T3 true ES2633343T3 (es) | 2017-09-20 |
Family
ID=47357694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12800251.6T Active ES2633343T3 (es) | 2011-06-13 | 2012-06-13 | Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9248198B2 (enExample) |
| EP (1) | EP2717897B1 (enExample) |
| JP (1) | JP6042425B2 (enExample) |
| KR (1) | KR102042015B1 (enExample) |
| CN (2) | CN103608026B (enExample) |
| AU (1) | AU2012271781C1 (enExample) |
| BR (1) | BR112013032108B1 (enExample) |
| CA (1) | CA2838662C (enExample) |
| DK (1) | DK2717897T3 (enExample) |
| ES (1) | ES2633343T3 (enExample) |
| IL (1) | IL229771B (enExample) |
| MX (1) | MX349146B (enExample) |
| PL (1) | PL2717897T3 (enExample) |
| WO (1) | WO2012174028A2 (enExample) |
| ZA (1) | ZA201309161B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2633343T3 (es) * | 2011-06-13 | 2017-09-20 | The Board Of Trustees Of The University Of Illionis | Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal |
| CN107427549B (zh) * | 2015-03-02 | 2022-01-11 | 伊利诺伊大学受托管理委员会 | 用于抑制血管生成的肽 |
| CN110128506B (zh) * | 2019-05-22 | 2021-03-30 | 中国药科大学 | 一种寡肽及其应用 |
| CN110664990B (zh) * | 2019-11-07 | 2021-03-16 | 江南大学 | 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用 |
| TW202204375A (zh) * | 2020-04-15 | 2022-02-01 | 美商寇峇有限公司 | 治療冠狀病毒感染之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
| GB9718609D0 (en) * | 1997-09-02 | 1997-11-05 | Imp College Innovations Ltd | Fusion protein |
| US7368430B2 (en) * | 2003-11-06 | 2008-05-06 | Research Development Foundation | Selective inhibitors of nuclear factor-κB activation and uses thereof |
| KR101206843B1 (ko) * | 2003-12-03 | 2012-11-30 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 튜불린 저해제 |
| AU2006292203A1 (en) * | 2005-09-21 | 2007-03-29 | Dask Technologies, Llc | Methods and compositions for organ and tissue functionality |
| KR101399175B1 (ko) * | 2006-07-21 | 2014-06-19 | 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 | 항염증성 및 항알레르기성 시클릭 펩티드 |
| US7585865B2 (en) * | 2006-07-21 | 2009-09-08 | The Penn State Research Foundation | Protein kinase C zeta inhibition to treat vascular permeability |
| KR20200075044A (ko) * | 2008-01-22 | 2020-06-25 | 아라임 파마슈티칼즈, 인크. | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
| FR2940032B1 (fr) | 2008-12-23 | 2013-08-09 | Seb Sa | Panier de cuisson d'aliments et systeme de cuisson correspondant |
| IT1392567B1 (it) * | 2008-12-24 | 2012-03-09 | Bioindustry Park Del Canavese S P A | Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario |
| US20100190691A1 (en) | 2009-01-27 | 2010-07-29 | Trojan Technologies, Ltd | Delivery of nucleic acids using cell-penetrating peptides |
| ES2633343T3 (es) * | 2011-06-13 | 2017-09-20 | The Board Of Trustees Of The University Of Illionis | Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal |
-
2012
- 2012-06-13 ES ES12800251.6T patent/ES2633343T3/es active Active
- 2012-06-13 BR BR112013032108-3A patent/BR112013032108B1/pt not_active IP Right Cessation
- 2012-06-13 CN CN201280029277.6A patent/CN103608026B/zh active Active
- 2012-06-13 MX MX2013014650A patent/MX349146B/es active IP Right Grant
- 2012-06-13 WO PCT/US2012/042118 patent/WO2012174028A2/en not_active Ceased
- 2012-06-13 PL PL12800251T patent/PL2717897T3/pl unknown
- 2012-06-13 DK DK12800251.6T patent/DK2717897T3/en active
- 2012-06-13 CA CA2838662A patent/CA2838662C/en active Active
- 2012-06-13 AU AU2012271781A patent/AU2012271781C1/en active Active
- 2012-06-13 CN CN201610552695.3A patent/CN106188232B/zh active Active
- 2012-06-13 EP EP12800251.6A patent/EP2717897B1/en active Active
- 2012-06-13 US US14/105,385 patent/US9248198B2/en active Active
- 2012-06-13 KR KR1020137033193A patent/KR102042015B1/ko not_active Expired - Fee Related
- 2012-06-13 JP JP2014515930A patent/JP6042425B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-03 IL IL229771A patent/IL229771B/en active IP Right Grant
- 2013-12-05 ZA ZA2013/09161A patent/ZA201309161B/en unknown
-
2014
- 2014-03-31 US US14/230,642 patent/US8912139B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX349146B (es) | 2017-07-14 |
| US9248198B2 (en) | 2016-02-02 |
| IL229771B (en) | 2019-07-31 |
| US8912139B2 (en) | 2014-12-16 |
| WO2012174028A3 (en) | 2013-02-21 |
| DK2717897T3 (en) | 2017-07-17 |
| EP2717897B1 (en) | 2017-04-19 |
| MX2013014650A (es) | 2014-01-24 |
| EP2717897A4 (en) | 2015-01-07 |
| BR112013032108A2 (pt) | 2016-11-22 |
| EP2717897A2 (en) | 2014-04-16 |
| US20140213505A1 (en) | 2014-07-31 |
| JP6042425B2 (ja) | 2016-12-14 |
| CN106188232B (zh) | 2020-01-07 |
| PL2717897T3 (pl) | 2017-09-29 |
| CN103608026B (zh) | 2016-08-24 |
| CA2838662A1 (en) | 2012-12-20 |
| AU2012271781B2 (en) | 2017-02-16 |
| CN103608026A (zh) | 2014-02-26 |
| CN106188232A (zh) | 2016-12-07 |
| WO2012174028A2 (en) | 2012-12-20 |
| ZA201309161B (en) | 2015-03-25 |
| AU2012271781A1 (en) | 2014-01-09 |
| KR102042015B1 (ko) | 2019-11-07 |
| US20140155314A1 (en) | 2014-06-05 |
| BR112013032108B1 (pt) | 2021-10-26 |
| KR20140056185A (ko) | 2014-05-09 |
| CA2838662C (en) | 2018-07-24 |
| AU2012271781C1 (en) | 2017-09-21 |
| JP2014518211A (ja) | 2014-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2633343T3 (es) | Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal | |
| AR078072A2 (es) | Un acido nucleico imi aislado recombinante, mutagenizado, o sintetico que comprende una secuencia de polinucleotidos de un acido nucleico imi1 de triticum aestivum casete de expresion celula huesped no humana, vector de transformacion y celula de planta transformada | |
| MX354555B (es) | Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso. | |
| CO2018014026A2 (es) | Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica | |
| BR112015024587A2 (pt) | variante de região fc | |
| HRP20191907T1 (hr) | 3´utr sekvence za stabilizaciju rnk | |
| EP2470559A4 (en) | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM | |
| MX2015012739A (es) | Composiciones y metodos para tratar la mucopolisacaridosis tipo 1. | |
| AR073666A1 (es) | Plantas transgenicas con rendimiento incrementado | |
| Hohn | Plant pararetroviruses: interactions of cauliflower mosaic virus with plants and insects | |
| Rutter et al. | Members of the Meloidogyne avirulence protein family contain multiple plant ligand-like motifs | |
| BR112014004827A2 (pt) | isopropilmalato sintase de nicotiana tabacum e métodos e usos dos mesmos | |
| AR103954A1 (es) | Análogos de amilina | |
| CO2020011027A2 (es) | Análogos de compstatina y sus usos médicos | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| CO6430475A2 (es) | Polipéptidos que tienen actividad de celulasa | |
| BR112015021210B1 (pt) | Método para reduzir a expressão de um ácido nucleico alvo em uma planta e ácido nucleico recombinante | |
| BR112015002918B8 (pt) | Construção de ácido nucleico compreendeendo uma região não traduzida, vetor e métodos para produção de um peptídeo ou uma proteína e para a expressão de um gene em uma planta ou células vegetais | |
| Budziszewska et al. | The role of the chloroplast in the replication of positive-sense single-stranded plant RNA viruses | |
| MX2017008587A (es) | Mirna natural para controlar la expresion de gen y uso del mismo. | |
| AR117629A2 (es) | Dominio de activación potente | |
| Ershova et al. | Nicotiana benthamiana kunitz peptidase inhibitor-like protein involved in chloroplast-to-nucleus regulatory pathway in plant-virus interaction | |
| CU24508B1 (es) | Composición farmacéutica que comprende péptido tipo apl | |
| RU2014144273A (ru) | Последовательности нуклеиновых кислот и пептиды/белки семейства ft, обусловливающие свойства подавления цветения у трансформированных ими растений табака и трансгенных растений | |
| MX2016003405A (es) | Hetero-transglicosilasa novedosa y usos de la misma. |